Related Experiment Video

Updated: May 4, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.2K

Therapeutic implications of immunogenic cell death in human cancer

Fabio Palombo1, Chiara Focaccetti1, Vincenzo Barnaba2

  • 1Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma , Rome , Italy.

Frontiers in Immunology
|January 17, 2014
PubMed

Insights

Dendritic cells (DCs) are key to immune responses against cancer. This review explores how DCs function in tumors and how treatments impact them, including new chemotherapy-associated antigens.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Dendritic cells (DCs) play a critical role in initiating adaptive immune responses.
  • DC function is highly context-dependent, varying across physiological conditions, inflammation, and cancer.
  • Tumor microenvironments and treatments significantly alter DC populations and functions.

Purpose of the Study:

  • To review the multifaceted roles of dendritic cells (DCs) in cancer immunity.
  • To explore the impact of cancer therapies on tumor-infiltrating DCs.
  • To summarize emerging evidence on chemotherapy-associated antigens in human cancers.

Main Methods:

  • Literature review of recent studies on dendritic cells in cancer.
  • Analysis of evidence regarding the effects of tumor treatments on DCs.
  • Compilation of data on chemotherapy-associated antigens.

Main Results:

  • DCs exhibit diverse subtypes and functions influenced by the tumor microenvironment.
  • Cancer therapies, particularly chemotherapy, can profoundly modulate DC subtypes and their anti-tumor activity.
  • Preliminary identification of chemotherapy-associated antigens offers new avenues for cancer immunotherapy.

Conclusions:

  • Dendritic cells are crucial regulators of anti-tumor immunity, with their roles dynamically altered by cancer and its treatments.
  • Understanding DC dynamics and identifying novel antigens are essential for developing effective cancer immunotherapies.
  • Further research into DC-targeted therapies and antigen discovery holds promise for improving cancer treatment outcomes.
Keywords:
chemotherapydendritic cells, T cellsimmunogenic cell deathtumor antigens

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
7.7K